Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer
Status:
Recruiting
Trial end date:
2026-01-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well the combination of apalutamide, abiraterone acetate, and
prednisone after chemotherapy work in treating patients that have received no prior treatment
(treatment naive) for high risk prostate cancer that is sensitive to androgen deprivation
therapy (castration sensitive) and has spread to other parts of the body (metastatic). This
study also aims to understand the inheritance of prostate cancer. If a gene or genes that
cause prostate cancer can be found, the diagnosis and treatment of prostate cancer may be
improved. Testosterone (a male hormone) can cause the growth of prostate cancer cells.
Hormone therapy using apalutamide may fight prostate cancer by blocking the use of
testosterone by the tumor cells. Antihormone therapy, such as abiraterone acetate, may lessen
the amount of testosterone made by the body. Anti-inflammatory drugs such as prednisone lower
the body's immune response and are used with other drugs in the treatment of some types of
cancer. Apalutamide, abiraterone acetate, and prednisone after chemotherapy may work better
in treating patients with castration sensitive prostate cancer.
Phase:
Phase 2
Details
Lead Sponsor:
OHSU Knight Cancer Institute
Collaborators:
Janssen Scientific Affairs, LLC National Cancer Institute (NCI) Oregon Health and Science University